NCT02692170View on ClinicalTrials.gov

A Study to Evaluate the Reactogenicity, Safety, and Immunogenicity of the Third Generation Hepatitis B Vaccine

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

December 7, 2012

Primary Completion Date

May 28, 2015

Study Completion Date

May 28, 2015

Conditions
Healthy
Interventions
BIOLOGICAL

CVI-HBV-001

Investigational Product

BIOLOGICAL

Conventional Hepatitis B vaccine (20 μg)

Investigational Product

All Listed Sponsors
lead

CHA Vaccine Institute Co., Ltd.

INDUSTRY

NCT02692170 - A Study to Evaluate the Reactogenicity, Safety, and Immunogenicity of the Third Generation Hepatitis B Vaccine | Biotech Hunter | Biotech Hunter